I am a healthcare professional
If you are a healthcare professional looking to find out more about heavy menstrual bleeding and contraception, please click below.
If you are not a healthcare professional and you want to learn about contraception please click below.
If you are not a healthcare professional and you want to learn about heavy menstural bleedingplease click below.
HCP

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

Bayer logo

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

Heavy menstrual bleeding (HMB) - when to investigate, treat or refer

This promotional meeting is part of the Women’s Health Matters Educational Programme that is organised and fully funded by Bayer

Nov 13 2019 | 19:30 - 20:30

Recorded: Nov 13 2019 | 19:30 - 20:30

Duration Time:

Description

  • Welcome & introduction
  • Learning objectives:
    • Identifying HMB, key questions to ask your patients
    • When do you need to examine?
    • What investigations are required?
    • What treatment options are available?
    • What are the ’red flags’ and who do you need to refer?
  • Question and Answer session with Dr Diana Mansour
  • Summary & close

Speakers

Pic

Dr Diana Mansour

Consultant in Community Gynaecology and Reproductive Health Care,

FSRH Senior Vice President,

Newcastle Hospitals, United Kingdom.

Dr Diana Mansour is a Consultant in Community Gynaecology and Reproductive Health Care and Associate Clinical Lecturer at the University of Newcastle since 1997. In addition Dr Mansour is the Senior Vice President for the Faculty of Sexual and Reproductive Healthcare.
 
Dr Mansour was the first accredited subspecialty trainee in Community Gynaecology and Reproductive Health Care of the Royal College of Obstetricians and Gynaecologists.
Dr Mansour is first author to over 90 peer-reviewed publications and has most recently published in Contraception and the BMJ SRH.
 
Dr Mansour’s areas of expertise include acceptability of contraceptive methods, non-contraceptive benefits of contraception, development of long-term methods of contraception, changes in health service provision, medical management of menstrual disorders and management of the menopause.

eventform

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk. Adverse events should also be reported to Bayer plc Tel: 01182063500, Fax: 01182063703, Email: pvuk@bayer.com.


If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.

  • PP-PF-WHC-GB-0437 August 2020

Copyright © 2019,
Bayer plc

This website is intended for UK healthcare professionals only. Women’s Health Matters is organised and funded by Bayer and contains promotional content.

Prescribing Information (PI) can be found via the links below:
Mirena® (52 mg intrauterine delivery system Levonorgestrel)
Kyleena® (19.5 mg intrauterine delivery system Levonorgestrel)
Jaydess® (13.5 mg intrauterine delivery system Levonorgestrel)
Qlaira® (estradiol valerate/dienogest)
Microgynon® (levonorgestrel/ethinylestradiol)

Page last modified Thu, 11/19/2020 - 12:00

Bayer logo